|Bid||112.00 x 800|
|Ask||139.00 x 900|
|Day's Range||114.29 - 115.82|
|52 Week Range||100.06 - 143.73|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||9.38|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||125.27|
# United Therapeutics Corp ### NASDAQ/NGS:UTHR View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive but appears to be weakening. Over the last month, growth of ETFs holding UTHR is favorable, with net inflows of $6.49 billion. This is among the highest periods of net inflows seen over the last one-year, but the rate of additional flows appears to be decreasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation and the immediately following Q&A session will take place on Monday, January 7, 2019, at 2:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
The investigation concerns whether United Therapeutics and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of United Therapeutics and are interested in obtaining additional information regarding this investigation, you are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 29, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved Pr Unituxin (dinutuximab ...
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.
United Therapeutics’ (UTHR) Remodulin generated revenues of $153.6 million in the third quarter, which reflected a decline of ~18% YoY (year-over-year).
United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.
Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment, ralinepag. The two companies said in a statement the deal for Arena's late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
CollPlant (CLGN) today announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics Corporation (UTHR) for 3D bioprinted lung transplants. As previously announced, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.